<H1>Chapter DOI: 10.1208/aapsj070102<br/>Cited-By Count: 20</H1><table border="1" width="30%"><tr><td>Total References</td><td>36</td></tr><tr><td>Springer references</td><td>3</td></tr><tr><td>Non Springer references</td><td>33</td></tr><tr><td>BibStructured Count</td><td width="10%">35</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>28</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity.<Emphasis Type="Italic">Toxicol Lett</Emphasis>; 2003;140&#8211;141:133&#8211;143.</td><td><a href=http://dx.doi.org/10.1016/S0378-4274(02)00497-6>10.1016/S0378-4274(02)00497-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2004;93:239&#8211;255.</td><td><a href=http://dx.doi.org/10.1002/jps.10545>10.1002/jps.10545</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions.<Emphasis Type="Italic">Eur J Clin Pharmacol</Emphasis>. 1999;55:341&#8211;347.</td><td><a href=http://dx.doi.org/10.1007/s002280050638>10.1007/s002280050638</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI.<Emphasis Type="Italic">In vitro</Emphasis> approaches to predicting drug interactions<Emphasis Type="Italic">in vivo</Emphasis>.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 1998;55:113&#8211;122.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(97)00239-6>10.1016/S0006-2952(97)00239-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions.<Emphasis Type="Italic">Toxicology</Emphasis>. 2000;153:1&#8211;10.</td><td><a href=http://dx.doi.org/10.1016/S0300-483X(00)00300-0>10.1016/S0300-483X(00)00300-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction.<Emphasis Type="Italic">Curr Opin Drug Discov Devel</Emphasis>. 2003;6:50&#8211;56.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2002;30:608&#8211;612.</td><td><a href=http://dx.doi.org/10.1124/dmd.30.5.608>10.1124/dmd.30.5.608</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2000;97:7500&#8211;7502.</td><td><a href=http://dx.doi.org/10.1073/pnas.130155097>10.1073/pnas.130155097</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.<Emphasis Type="Italic">Endocr Rev.</Emphasis> 2002;23:687&#8211;702.</td><td><a href=http://dx.doi.org/10.1210/er.2001-0038>10.1210/er.2001-0038</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for<Emphasis Type="Italic">CYP3A</Emphasis> induction.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1998;95:12208&#8211;12213.</td><td><a href=http://dx.doi.org/10.1073/pnas.95.21.12208>10.1073/pnas.95.21.12208</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate<Emphasis Type="Italic">CYP3A4</Emphasis> gene expression and cause drug interactions.<Emphasis Type="Italic">J Clin Invest.</Emphasis> 1998;102:1016&#8211;1023.</td><td><a href=http://dx.doi.org/10.1172/JCI3703>10.1172/JCI3703</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2004;33:38&#8211;48.</td><td><a href=http://dx.doi.org/10.1124/dmd.104.001594>10.1124/dmd.104.001594</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Raucy JL, Warfe, L, Yueh M-F, Allen SW. A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;303:412&#8211;423.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.038653>10.1124/jpet.102.038653</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Marks BD, Smith RW, Braun HA, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid<Superscript>&#174;</Superscript> P450 substrate.<Emphasis Type="Italic">Assay Drug Dev Technol</Emphasis>. 2002;1:73&#8211;81.</td><td><a href=http://dx.doi.org/10.1089/154065802761001329>10.1089/154065802761001329</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Venkatesan K. Pharmacokinetic drug interactions with rifampicin.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1992;22:47&#8211;65.</td><td><a href=http://dx.doi.org/10.2165/00003088-199222010-00005>10.2165/00003088-199222010-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications.<Emphasis Type="Italic">Cancer Treat Rev</Emphasis>. 2001;27:221&#8211;233.</td><td><a href=http://dx.doi.org/10.1053/ctrv.2001.0228>10.1053/ctrv.2001.0228</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers.<Emphasis Type="Italic">Cancer Invest</Emphasis>. 2003;21:887&#8211;896.</td><td><a href=http://dx.doi.org/10.1081/CNV-120025092>10.1081/CNV-120025092</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.<Emphasis Type="Italic">Blood</Emphasis>. 2003;101:3628&#8211;3634.</td><td><a href=http://dx.doi.org/10.1182/blood-2002-07-2283>10.1182/blood-2002-07-2283</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole.<Emphasis Type="Italic">Hum Exp Toxicol</Emphasis>. 1999;18:95&#8211;105.</td><td><a href=http://dx.doi.org/10.1191/096032799678839699>10.1191/096032799678839699</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zlokarnik</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Volak</span> <span style='background:#DDDDDD'>LP</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Andrew</span> <span style='background:#DDDDDD'>MM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tran</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Cleveland</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Makings</span> <span style='background:#DDDDDD'>LR.</span></span>, <span style='background:#BDBAD6'>Novel fluorescent probes detect different types of CYP450-drug interactions in high throughput mode. Gordon Research Conference on Drug Metabolism; July 9&#8211;14,</span></aug> <span style='background:#66FF66'>2000</span>; <span style='background:#C0FFC0'>Plymouth, NH</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions.<Emphasis Type="Italic">Child Adolesc Psychiatr Clin N Am</Emphasis>. 2000;9:43&#8211;76.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.<Emphasis Type="Italic">Drug Metab. Dispos.</Emphasis> 2001;29:1644&#8211;1651.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Shen L, Fitzloff JF, Cook CS. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2004;32:186&#8211;196. doi:10.1124/DMD.32.2.186</td><td><a href=http://dx.doi.org/10.1124/dmd.32.2.186>10.1124/dmd.32.2.186</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2001;21:397&#8211;411.</td><td><a href=http://dx.doi.org/10.1002/med.1016>10.1002/med.1016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:133&#8211;157.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.133>10.1146/annurev.pharmtox.40.1.133</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Michalets EL. Update: clinically significant cytochrome P450 drug interactions.<Emphasis Type="Italic">Pharmacotherapy</Emphasis>. 1998;18:84&#8211;112.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2000;38:41&#8211;57.</td><td><a href=http://dx.doi.org/10.2165/00003088-200038010-00003>10.2165/00003088-200038010-00003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibChapter</td><td>Parkinson A, Madan A, Forster J, et al. Enzyme induction: assessing the potential for drug interactions. In: Hori W, ed.<Emphasis Type="Italic">Drug-Drug Interactions: Analyzing in vitro-in vivo correlations</Emphasis>. Westborough, Massachusetts: International Business Communications, Inc; 1997, 1&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Caldwell GW. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physiochemical, in vitro and in vivo screens.<Emphasis Type="Italic">Curr Opin Drug Discov Devel</Emphasis>. 2000;3:30&#8211;41.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.2174/1567204043396677>10.2174/1567204043396677</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Fuhr U, Weiss M, Kroemer HK, et al. Systematic screening for pharmacokinetic interactions during drug development.<Emphasis Type="Italic">J Clin Pharmacol Therap</Emphasis>. 1996;34:139&#8211;151.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Rodrigues AD. Use of<Emphasis Type="Italic">in vitro</Emphasis> human metabolism studies in drug development: An industrial perspective.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 1994;48:2147&#8211;2156.</td><td><a href=http://dx.doi.org/10.1016/0006-2952(94)00312-2>10.1016/0006-2952(94)00312-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human, hepatocytes.<Emphasis Type="Italic">J Pharmacol, Exp Ther</Emphasis>. 2002;302:475&#8211;482.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.033837>10.1124/jpet.102.033837</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2003;31:533&#8211;539.</td><td><a href=http://dx.doi.org/10.1124/dmd.31.5.533>10.1124/dmd.31.5.533</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.<Emphasis Type="Italic">Drug Metab. Disp.</Emphasis> 2002;30:795&#8211;804.</td><td><a href=http://dx.doi.org/10.1124/dmd.30.7.795>10.1124/dmd.30.7.795</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Plant NJ, Ogg MS, Crowder M, Gibson GG. Control and statistical analysis of<Emphasis Type="Italic">in vitro</Emphasis> reporter gene assays.<Emphasis Type="Italic">Anal Biochem</Emphasis>. 2000;278:170&#8211;174.</td><td><a href=http://dx.doi.org/10.1006/abio.1999.4460>10.1006/abio.1999.4460</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Spink BC, Hussain MM, Katz BH, Eisele L, Spink DC. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells indirubin.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2003;66:2313&#8211;2321.</td><td><a href=http://dx.doi.org/10.1016/j.bcp.2003.08.019>10.1016/j.bcp.2003.08.019</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>